Antibodies News and Research

RSS

Battery-free wearable sensor continuously monitors health through sweat

University of California, Irvine researchers have invented a wearable, wireless, battery-free, bioelectronic sensor to monitor users' health by analyzing molecular biomarkers in human sweat.

13 May 2026

Next-generation cancer therapy shows early promise as treatment candidate for glioblastoma

A next-generation cancer therapy being developed at McMaster University has shown early promise as a treatment candidate for glioblastoma, the most aggressive and most common type of primary brain cancer in adults.

13 May 2026

New mRNA adjuvant dramatically boosts T-cell vaccine responses in mice

MIT engineers have developed a new way to amplify the T-cell response to mRNA vaccines - an advance that could lead to much more powerful cancer vaccines and stronger protection against infectious diseases.

13 May 2026

Antibodies targeting GPNMB may slow Parkinson's disease progression

Monoclonal antibodies can block a key immune‑related protein that drives the spread of brain cell damage in Parkinson's disease (PD).

12 May 2026

Nuclera launches antibody triage service to advance AI-driven antibody discovery

Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its antibody screening service to streamline the transition from antibody hit generation to lead selection.

From Nuclera 11 May 2026

Rockefeller scientists reveal how HIV strains escape broadly neutralizing antibodies

Broadly neutralizing antibodies (bNAbs) are among the most promising new treatments for HIV, offering the potential to forego traditional daily dose of antiretroviral drugs.

11 May 2026

Slow and steady wins: Low-dose peanut immunotherapy safely desensitizes 82% of preschoolers in landmark trial

A Swedish randomized trial found that slow up-dosing peanut oral immunotherapy with a low maintenance dose helped 82% of preschool children achieve sustained peanut tolerance after three years. The approach proved safer than conventional protocols, with severe reactions uncommon and strong family adherence throughout treatment.

10 May 2026

Infectious H5N1 virus detected in dairy farm air

Findings from California dairy farms show H5N1 in air and wastewater, indicating overlooked transmission routes and implications for outbreak management.

8 May 2026

JAYseq test delivers rapid genomic profiling for multiple myeloma patients

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of JAYseqTM, a clinical whole-genome sequencing (WGS) test specifically for multiple myeloma.

7 May 2026

Scientists identify powerful human antibodies capable of neutralizing measles virus

Scientists at La Jolla Institute for Immunology (LJI) are the first in the world to characterize human antibodies capable of neutralizing measles virus.

7 May 2026

Antibodies.com awarded King's Award for Enterprise in International Trade

Antibodies.com has been awarded a 2026 King's Award for Enterprise in the International Trade category – one of the UK's highest business honors.

From Antibodies.com 7 May 2026

CGRP inhibitors may reduce glaucoma risk among migraine patients

A type of drug used to prevent migraine may be associated with a reduced risk of glaucoma, according to a study published May 6, 2026, in Neurology®, the medical journal of the American Academy of Neurology.

6 May 2026

H5N1 spreads through multiple routes on infected dairy farms

The H5N1 strain of highly pathogenic avian influenza H5N1 has been detected in over 700 herds of dairy cows in California, the largest dairy-producing state in the U.S.

5 May 2026

Phase 2 human clinical trial paves way for effective hookworm vaccine

A phase 2 human clinical trial of an antigen for a parasitic infection caused by hookworms has been shown to be effective in limiting the intensity of infection, paving the way for the development of a vaccine.

5 May 2026

Multiple myeloma mortality rates decline with advances in targeted therapies

A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis from 1975 to 2023."

29 Apr 2026

Maternal antibodies provide lifelong protection against adult gum disease

Mothers provide a hidden immune legacy that protects their children's teeth long after weaning is over. A new study reveals how maternal antibodies act as early life architects, programming the mouth to resist aggressive bacteria and prevent the bone loss associated with adult gum disease.

29 Apr 2026

New map reveals B cell clusters linked to faster diabetic kidney disease

A detailed new map of the human kidney revealed a previously unrecognized form of diabetic kidney disease (DKD) marked by clusters of immune cells-specifically B cells-that are linked to faster disease progression.

29 Apr 2026

New vaccine strategy neutralizes diverse HIV variants

Researchers at Karolinska Institutet, in collaboration with colleagues at The Scripps Research Institute and Emory University, have developed a new vaccine strategy that has generated antibodies capable of neutralising highly divergent HIV variants.

29 Apr 2026

Addgene reinforces its expanding role in research with new brand

Addgene, a purpose-driven organization that joins with scientists around the world to reduce barriers to research and foster innovation, today announced that its strategic growth and expanded services have driven the organization’s refreshed brand.

29 Apr 2026

Scientists redesign CAR-T cells to fight more than cancer

This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic viral infections, and next-generation immune-cell platforms. It highlights promising engineering advances, including universal CAR-T cells, in vivo delivery, CAR-NK cells, and safety switches, while emphasizing unresolved challenges in durability, safety, scalability, and global access.

29 Apr 2026